Inhibitors of DPP-4, such as sitagliptin, vildagliptin and linagliptin, inhibit DPP-4, resulting in an increase of incretin and GLP-1 secretion (Figure 1), leading to an improvement in plasma glucose control without inducing hypoglycemia or increasing the body weight.69 Both types of drugs are barely metabolized in the liver and are excreted unchanged by the kidney;70 thus, they seem to be safe in cirrhotic patients.71 Unlike the old antidiabetic drugs, their pharmacodynamic characteristics have been assessed in patients with varying degrees of hepatic impairment and their safety has been assessed in studies comprising large number of individuals
Question 2: Are you cash-pay with no GLP-1 coverage and is price the dominant factor
Note: If you experience swelling of the throat, face, or tongue, or have any difficulty breathing, call emergency services immediately, as these are signs of an anaphylactic reaction
MarketScan data for this article represents commercial claims incurred January 2020 December 2024
GHK-Cu is a copper peptide associated with collagen production, tissue regeneration, and recovery support